MARKET

PERCF

PERCF

Percheron Therapeutics
OTCPK
0.010
NaN%
Closed 09:30 12/05 EST
OPEN
--
PREV CLOSE
0.010
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.010
52 WEEK LOW
0.0021
MARKET CAP
10.87M
P/E (TTM)
-1.0417
1D
5D
1M
3M
1Y
5Y
1D
Percheron Therapeutics Updates Corporate Presentation with New Program Insights
TipRanks · 11/04 22:55
Percheron Therapeutics Advances HMBD-002 with Positive Trial Results
TipRanks · 10/31 00:17
Percheron Therapeutics Reports Strong Shareholder Support at AGM
TipRanks · 10/22 03:28
Percheron Therapeutics Unveils Future Plans at AGM
TipRanks · 10/22 01:28
Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002
Barchart · 10/07 17:20
Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development
TipRanks · 09/29 22:58
Percheron Therapeutics Strengthens Leadership Team to Advance Cancer Therapy
TipRanks · 09/23 03:37
Percheron Therapeutics Announces 2025 Annual General Meeting
TipRanks · 09/22 00:08
More
About PERCF
Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

Webull offers Percheron Therapeutics Ltd stock information, including OTCPK: PERCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PERCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PERCF stock methods without spending real money on the virtual paper trading platform.